论文部分内容阅读
本刊讯(《中国医药导报》记者王丽)6月27日,浙江中医药大学在京宣布,其具有自主知识产权的抗癌中药康莱特注射液已经美国FDA认可通过,进入三期临床,在美国癌症患者中扩大使用。这标志着我国中药国际化迈出了至为关键的一步。据浙江中医药大学副校长李俊伟介绍,康莱特注射液是中国工程院院士、浙江中医药大学研究员李大鹏领衔的科研团队,从中药薏苡仁中提取分离出抗癌活性成分研制而成的静脉乳剂,其对胰腺癌、肺癌、肝癌等中晚期恶性肿瘤具有显著的治疗效果,同时克服
On June 27, Zhejiang University of Traditional Chinese Medicine announced in Beijing that Kanglaite Injection, an anti-cancer Chinese medicine with independent intellectual property rights, has been approved by the U.S. FDA and entered the phase III clinical trial. US cancer patients to expand the use of. This indicates that the internationalization of Chinese medicine has taken a crucial step. According to Li Junwei, vice president of Zhejiang University of Traditional Chinese Medicine introduced Kanglaite injection is the Chinese Academy of Engineering, Zhejiang University of Chinese Medicine researcher led by Li Dapeng research team from the Chinese medicine Yiyiren isolated anticancer active ingredients developed from intravenous emulsion, its For pancreatic cancer, lung cancer, liver cancer and other advanced malignant tumors have a significant therapeutic effect, while overcoming